A Phase 4 interventional study of Sensipar® and Vitamin D in Secondary Hyperparathyroidism, sponsored by Amgen. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-02-11.
Sponsored by Amgen · Phase 4, Interventional, and Treatment
The purpose of this study is to compare the proportion of chronic kidney disease (CKD) subjects on dialysis receiving Sensipar® and low dose vitamin D or escalating doses of vitamin D alone who are able to achieve the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKF-K/DOQI) secondary hyperparathyroidism (HPT) treatment targets for both biointact parathyroid hormone (biPTH) and calcium-phosphorus (Ca x P) product.
3,517 studies on the registry are indexed under Neoplasm Metastasis; 885 are open to participants now.
This study's enrollment of 170 is above the median of 54 across 2,767 interventional studies indexed under Neoplasm Metastasis.
Browse Neoplasm Metastasis studies →Amgen is the lead sponsor of 1,015 studies on the registry; 49 are open to participants now.
Of its 245 completed or terminated interventional studies of FDA-regulated products, 159 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria: - On hemodialysis for at least 3 months and have received intravenous vitamin D therapy (paricalcitol or doxercalciferol) for at least 3 months prior to entering screening - Historical iPTH 150-800 pg/ml (or biPTH 80-430 pg/ml) within 6 months and corrected serum Ca greater than 8.4 mg/dl within 2 months prior to screening period. For subjects with biPTH 80-160 pg/ml (iPTH 150-300 pg/ml), Ca x P must be greater than 55 mg²/dl² within 2 months prior to the screening period - Screening (pre-washout) biPTH 80-430 pg/ml and a corrected serum Ca level greater than 8.4 mg/dl. For subjects with biPTH 80-160 pg/ml Ca x P must be also greater than 55 mg²/dl² - Baseline mean biPTH (post-washout) greater than 160 pg/ml and mean corrected Ca greater than 8.4 mg/dl Exclusion Criteria: - Parathyroidectomy in the 3 month period prior to screening - Current gastrointestinal disorder that may be associated with impaired absorption of orally administered medications or an inability to swallow tablets - Use of investigational drug or device or participation in a trial of investigational drug or device within 30 days of screening - Females of child bearing potential who are pregnant (e.g., positive pregnancy test) or are breast feeding or who refuse to use highly effective contraceptive measures (as determined by the investigator) throughout the study - Previously participated in this or any other Sensipar® study or has received or is receiving Sensipar® as a commercially available product
Cinacalcet and low-dose IV Vitamin D
Drug: Sensipar® · Drug: Vitamin D
Escalating doses of IV Vitamin D alone
Drug: Vitamin D
Cinacalcet hydrochloride
Also known as: Cinacalcet hydrochloride, Cinacalcet HCL, Cinacalcet
Vitamin D administered IV
Also known as: paricalcitol, doxercalciferol
Achieving the NKF-K/DOQI targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (less than 55 mg^2/dL^2) during the assessment phase
Proportion of subjects in each treatment group simultaneously achieving the National Kidney Foundation - Kidney Disease Outcome Quality Initiative (NKF-K/DOQI) targets for both biPTH (80-160 pg/mL, equivalent to iPTH 150-300 pg/mL) and Ca x P (\< 55 mg\^2/dL\^2) during the assessment phase (last 11 weeks of study following a 16-week titration phase)
Time frame: Weeks 17 - 27
Absolute Change from Baseline for P During the Assessment Phase
Absolute change from baseline for serum phosphorus (P) during the assessment phase
Time frame: Baseline to weeks 17-27
Proportion of Participants with ≥ 30% Reduction from Baseline in Mean iPTH During the Assessment Phase
Proportion of participants with ≥ 30% reduction from baseline in mean intact parathyroid hormone (iPTH) during the assessment phase.
Time frame: Baseline and Weeks 17-27
Percent Change from Baseline for Calcium During the Assessment Phase
Percent Change from Baseline for Calcium (Ca) During the Assessment Phase
Time frame: Baseline to weeks 17-27
Percent Change from Baseline for Phosphorus During the Assessment Phase
Percent change from baseline for Phosphorus (P) during the assessment phase
Time frame: Baseline to weeks 17-27
Percent Change from Baseline for Ca x P During the Assessment Phase
Percent change from baseline for calcium x phosphorus (Ca x P) during the assessment phase
Time frame: Baseline to weeks 17-27
Percent Change from Baseline for iPTH During the Assessment Phase
Percent change from baseline for intact parathyroid hormone (iPTH) during the assessment phase
Time frame: Baseline to weeks 17-27
Proportion of Participants who Attained the K/DOQI Target Range for Ca x P During the Assessment Phase.
Proportion of participants who attained the K/DOQI target range for calcium x phosphorus (Ca x P) during the assessment phase.
Time frame: Weeks 17 - 27
Proportion of Participants who Attained the K/DOQI Target Range for Ca During the Assessment Phase
Proportion of participants who attained the K/DOQI target range for calcium (Ca) during the assessment phase.
Time frame: Weeks 17-27
Proportion of Participants who Attained the K/DOQI Target Range for iPTH During the Assessment Phase
Proportion of participants who attained the K/DOQI target range for intact parathyroid hormone (iPTH) during the assessment phase.
Time frame: Weeks 17-27
Proportion of Participants who Attained the K/DOQI Target Range for P During the Assessment Phase.
Proportion of participants who attained the K/DOQI target range for phosphorus (P) during the assessment phase.
Time frame: Weeks 17-27
Absolute Change from Baseline for iPTH During the Assessment Phase
Absolute change from baseline for intact parathyroid hormone (iPTH) during the assessment phase.
Time frame: Baseline to weeks 17-27
Absolute Change from Baseline for Ca During the Assessment Phase
Absolute change from baseline for calcium (Ca) during the assessment phase
Time frame: Baseline to weeks 17-27
Absolute Change from Baseline for Ca x P During the Assessment Phase
Absolute change from baseline for calcium x phosphorus (Ca x P) during the assessment phase.
Time frame: Baseline to weeks 17-27
No study locations are listed for this record.
This study is completed, as verified in Feb 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Amgen